ALKERMES, INC.
🇺🇸United States
Clinical Trials
131
Active:48
Completed:70
Trial Phases
5 Phases
Early Phase 1:1
Phase 1:63
Phase 2:16
+2 more phases
Drug Approvals
6
NMPA:3
FDA:3
Drug Approvals
Risperidone for Depot Suspension
- Product Name
- 注射用利培酮微球
- Approval Number
- 国药准字HJ20150267
- Approval Date
- Oct 30, 2020
NMPA
Risperidone for Depot Suspension
- Product Name
- 注射用利培酮微球
- Approval Number
- 国药准字HJ20150269
- Approval Date
- Oct 30, 2020
NMPA
Risperidone for Depot Suspension
- Product Name
- 注射用利培酮微球
- Approval Number
- 国药准字HJ20150268
- Approval Date
- Oct 30, 2020
NMPA
Clinical Trials
Distribution across different clinical trial phases (115 trials with phase data)• Click on a phase to view related trials
Phase 1
63 (54.8%)Phase 3
31 (27.0%)Phase 2
16 (13.9%)Phase 4
3 (2.6%)Early Phase 1
1 (0.9%)phase_2_3
1 (0.9%)A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia
- First Posted Date
- 2025-02-25
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT06843590
- Locations
- 🇺🇸
Alkermes Investigator Site, Sugarland, Texas, United States
🇺🇸Alkermes Investigational Site, San Antonio, Texas, United States
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy
Phase 2/3
Recruiting
- Conditions
- Narcolepsy Type 1 and Type 2
- First Posted Date
- 2025-01-10
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Alkermes Inc.
- Target Recruit Count
- 58
- Registration Number
- 2024-519822-18-00
- Locations
- 🇪🇸
Alkermes Investigational Site, Madrid, Spain
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT06555783
- Locations
- 🇦🇺
Alkermes Investigator Site, Bedford Park, South Australia, Australia
🇪🇸Alkermes Investigational Site, Madrid, Spain
🇮🇹Alkermes Investigational site, Verona, Italy
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT06358950
- Locations
- 🇪🇸
Alkermes Investigational Site, Madrid, Spain
🇦🇺Alkermes Investigator Site, Bedford Park, South Australia, Australia
Study of the Breast Milk Pharmacokinetics of Olanzapine and Samidorphan
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05547100
- Locations
- 🇺🇸
Alkermes Investigator Site, Las Vegas, Nevada, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 16
- Next
News
No news found